Behavioral health, at scale

Woebot is designed to help the unsolved problems in behavioral health. It aims to:

  • Address: increase equitable access and improve patient/member experience through always available mental health support
  • Activate: drive activation and overall satisfaction among your populations with multi-channel engagement campaigns and a configurable deployment strategy
  • Capture: deliver population health insights, engagement and satisfaction measures through an analytics dashboard, Spotlight
  • Impact: leverage population health measures with the goal of influencing quality scores
Quintuple aim visualQuintuple aim visualQuintuple aim visual

Woebot Health Platform is the foundational development platform where components are used for multiple types of products in different stages of development and enforced under different regulatory guidances


Built for accessibility and impact

24 %

reduction in overall work impairment1

24 %

reduction in burnout2

75 %

of messages are sent on weekends or outside of traditional working hours (9-5), with the longest 'sessions' happening between 2-5am*

Woebot for Mood & Anxiety (W-MA-02) is an investigational medical device. It has not been evaluated, cleared, or approved by the FDA. Not for use outside an IRB-approved clinical trial. Results are based on self-reported survey response and were all collected at 8-weeks end-of-treatment in the study. 1N = 91 internal analysis 2N = 234 internal analysis

 

*Platform data as of June 2024


How Woebot works

Woebot is available for in-the-moment mental health support, delivered through an app on a phone or tablet that can:

  • be used as a wellness support tool or clinically adjunctive support tool
  • provides user-directed, always available, interactive conversations and tools
  • encourage healthy lifestyle choices, which may help individuals live well with symptoms of anxiety and depression

Through conversations, Woebot helps users develop skills for emotional regulation and supports mood monitoring and management, with tools such as:

  • mood tracking
  • progress reflection
  • gratitude journaling
  • mindfulness practice

Woebot is not generative AI like ChatGPT. It’s rules-based. Woebot’s conversations are written by conversational writers using elements from Cognitive Behavioral Therapy (CBT), Interpersonal Psychotherapy (IPT) and Dialectical Behavioral Therapy (DBT), along with collaboration from our clinical experts. 

Available now, non-prescription:

  • Woebot for Adults: A tool to help people develop coping skills for symptoms of anxiety and depression
  • Woebot for Adolescents: A tool built for an adolescent’s (13-17 year old) dynamic and actively developing mind

Woebot for Adults and Woebot for Adolescents are not evaluated, cleared or approved by the FDA. They may be considered as an adjunct to clinical care; they do not replace clinical care. 


Population Insights

Spotlight, our data analytics platform, and team aggregates insights from Woebot, including: 

  • Patient/member top focus areas and concerns
  • Quality measure scores
  • SDOH insights
  • Engagement and satisfaction measures
  • Concerning language recognition*

With the goal of automating measurement capture for clinicians and increasing visibility beyond the traditional four walls of care. 

Image of Spotlight dashboard and user conversationImage of Spotlight dashboard and user conversationImage of Spotlight dashboard and user conversation

Image(s) of the Spotlight Dashboard are an example of an implementation for adjunctive use. Woebot Health Platform is the foundational development platform where components are used for multiple types of products in different stages of development and enforced under different regulatory guidances.

*Woebot does not provide crisis counseling and is not a suicide prevention or crisis intervention service. Concerning language is not reviewed or assessed internally at Woebot Health in real-time for intervention and such data is not used for managing potential crises or any acute or non-acute patient safety issue. Discomfort may be experienced when answering sensitive questions. Temporary upset may occur as a result of discontinued access.


Connect with us

Together, we can build a more accessible, equitable, and effective system that prioritizes the well-being of individuals and communities.


ORCHA does not follow the Federal Food, Drug, and Cosmetic Act and therefore ORCHA certification does not denote clearance or approval by the U.S. Food and Drug Administration (FDA).